Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at thalidomide for cancer patients with weight loss
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is trying to find out if thalidomide helps cancer patients who have severe weight loss (cachexia).
Cachexia is more complicated than just loss of appetite and weight loss. It is a complex problem that involves changes in metabolism and leads to problems such as muscle wasting.
Cachexia seems to be linked to the production of body chemicals called cytokines. Cancers can produce cytokines in larger amounts than normal. The cytokines can then cause the body to break down fat and muscle faster than normal.
Researchers think that thalidomide may be able to help with cachexia. Thalidomide can reduce the amount of cytokines in the body. So it may be able to slow down, or even stop, the weight loss they cause. Early trial results are promising, but no one is quite sure yet how well it works.
In this trial, some patients will have thalidomide tablets and some will have dummy tablets (placebo tablets). The aim of the trial is to find out if thalidomide can help stop cachexia. And to find out how it affects patients’ quality of life.
Who can enter
You can enter this trial if you
- Have cancer of the gullet (oesophagus), stomach (gastric cancer), small bowel (duodenum or ileum) or pancreas
- Are not able to have treatment aimed at curing your cancer
- Have lost 5% of your body weight or are losing at least 1 kg (2.2 lbs) per month
- Are able to take tablets
- Are prepared to use reliable contraception and are willing to have a pregnancy test once a month if there is any chance you could become pregnant
- Are at least 18 years old
You cannot enter this trial if you
- Have had chemotherapy or radiotherapy in the last 4 weeks
- Are due to have chemotherapy or radiotherapy in the next 6 months
- Are taking varying doses of megesterol acetate (Megace) or eicosapentaenoic acid - if you are taking a stable dose and are still losing weight, you may still be able to join the trial
- Are taking part in any other trial
- Are pregnant or breastfeeding
- Have numbness or tingling in your hands or feet (peripheral neuropathy)
- Have severe constipation
- Have vertigo, or have dizzy spells caused by vestibular disease of the ear
- Have had an allergic reaction to thalidomide in the past
This is a randomised trial. It will recruit 180 people into 2 groups. The people taking part will be put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.
Group 1 take thalidomide tablets once a day (at night) for 6 months.
Group 2 take dummy tablets (placebo tablets) once a day (at night) for 6 months.
You will fill out a questionnaire before you start treatment, and again at 1 month, 2 months, 3 months and 6 months. It will ask you how you have been feeling and about any side effects you have had. It is called a quality of life questionnaire.
You will see the doctors and have some tests before you take part in this trial. The tests include
- Blood tests
- Urine test
- Examination of your nervous system (neurological examination)
- Height and weight
- Body fat measurements
- Lean body mass measurements
- Grip strength
During the trial you will see the doctors at 1 month, 2 months, 3 months and 6 months. At each visit you will have your body fat and lean body mass measured again. At most visits you will also have blood tests and a urine test. The doctor will ask you how you have been, and give you a supply of tablets to last until your next visit.
A month after you stop taking the thalidomide (or placebo), a member of the research team will phone you to see how you are.
How to join a clinical trial
Dr S Green
NIHR Clinical Research Network: Cancer
National Health Service (NHS)
Portsmouth Hospitals NHS Trust